Payment overview · 2025
General Payments
$58,519.24
41 reported records · 14 companies
Healthcare provider profile · identity verified
H J Wedner, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Allergy & Immunology · SAINT LOUIS, MO · NPI 1386661809
Verified facts
What the public records show
CMS Open Payments records show H J Wedner, MD received $58,519.24 in general payments during 2025 across 41 reported records.
Ionis Pharmaceuticals, Inc. accounted for 57.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ayvakit, Takhzyro, Xolair.
Blueprint Medicines Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AYVAKIT as an associated drug or biological on 4288 records involving 3006 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ayvakit by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Haegarda as an associated drug or biological on 3692 records involving 1703 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Haegarda by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Hizentra as an associated drug or biological on 13634 records involving 4691 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Hizentra by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AYVAKIT as an associated drug or biological on 4791 records involving 3585 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ayvakit by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xolair as an associated drug or biological on 11057 records involving 4008 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xolair by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
SANOFI US SERVICES INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AYVAKIT as an associated drug or biological on 563 records involving 263 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ayvakit by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAKHZYRO as an associated drug or biological on 3355 records involving 1604 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Takhzyro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33,617.79 | 57.5% | 19 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16,295.95 | 27.9% | 7 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $2,140.00 | 3.7% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $1,771.29 | 3.0% | 3 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $1,438.00 | 2.5% | 1 | 2025 |
| SANOFI US SERVICES INC. | Unresolved — no canonical attribution shown | $1,330.00 | 2.3% | 1 | 2025 |
| Grifols Shared Services North America, Inc. | Unresolved — no canonical attribution shown | $950.00 | 1.6% | 1 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $498.75 | 0.8% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $124.84 | 0.2% | 2 | 2025 |
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $123.23 | 0.2% | 1 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $116.64 | 0.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $92.70 | 0.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.99 | 0.0% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $1.06 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,725.00 | 9 |
| Consulting Fee | $17,058.00 | 3 |
| Travel and Lodging | $5,291.52 | 14 |
| Food and Beverage | $945.97 | 14 |
| Honoraria | $498.75 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DAWNZERA Normalized: dawnzera |
Drug | Ionis Pharmaceuticals, Inc. | $30,777.79 | 18 | 2025 |
Source payment records
|
|||||
| TAKHZYRO Normalized: takhzyro |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $16,295.95 | 7 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols Shared Services North America, Inc., Grifols USA, LLC | $3,090.00 | 2 | 2025 |
Source payment records
|
|||||
| DONIDALORSEN Normalized: donidalorsen |
Drug | Ionis Pharmaceuticals, Inc. | $2,840.00 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological, Drug | Blueprint Medicines Corporation, SANOFI US SERVICES INC. | $1,828.75 | 2 | 2025 |
Source payment records
|
|||||
| Xolair Normalized: xolair |
Biological | Genentech USA, Inc. | $1,771.29 | 3 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $1,438.00 | 1 | 2025 |
Source payment records
|
|||||
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst US Sales Co., LLC | $123.23 | 1 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $116.64 | 1 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $106.60 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| VTAMA Normalized: vtama |
Drug | Organon LLC | $1.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AYVAKIT ayvakit |
2025 | Ayvakit | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TAKHZYRO takhzyro |
2025 | Takhzyro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Xolair xolair |
2025 | Xolair | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Blueprint Medicines Corporation Exact reporting entity; no affiliate inference |
2025 | AYVAKIT open payments reported associated product |
CMS Open Payments — General Payments 4288 supporting records · 3006 recipient NPIs · example record 1235804861 |
Ayvakit · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Haegarda open payments reported associated product |
CMS Open Payments — General Payments 3692 supporting records · 1703 recipient NPIs · example record 1232339032 |
Haegarda · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Hizentra open payments reported associated product |
CMS Open Payments — General Payments 13634 supporting records · 4691 recipient NPIs · example record 1232339012 |
Hizentra · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | AYVAKIT open payments reported associated product |
CMS Open Payments — General Payments 4791 supporting records · 3585 recipient NPIs · example record 1233194960 |
Ayvakit · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Xolair open payments reported associated product |
CMS Open Payments — General Payments 11057 supporting records · 4008 recipient NPIs · example record 1211488440 |
Xolair · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| SANOFI US SERVICES INC. Exact reporting entity; no affiliate inference |
2025 | AYVAKIT open payments reported associated product |
CMS Open Payments — General Payments 563 supporting records · 263 recipient NPIs · example record 1233195888 |
Ayvakit · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TAKHZYRO open payments reported associated product |
CMS Open Payments — General Payments 3355 supporting records · 1604 recipient NPIs · example record 1223616316 |
Takhzyro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 281 | 78 |
| Fluticasone Propionate | Fluticasone Propionate | 178 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 53 |
| Ipratropium Bromide | Ipratropium Bromide | 151 | 52 |
| Breo Ellipta | Fluticasone/Vilanterol | 99 | 17 |
| Azelastine Hcl | Azelastine Hcl | 89 | 30 |
| Famotidine | Famotidine | 81 | 23 |
| Doxepin Hcl | Doxepin Hcl | 62 | 11 |
| Dupixent Syringe | Dupilumab | 62 | suppressed |
| Epinephrine | Epinephrine | 59 | 38 |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 50 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | 11 |
| Prednisone | Prednisone | 35 | 23 |
| Takhzyro | Lanadelumab-Flyo | 35 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 35 | 12 |
| Icatibant | Icatibant Acetate | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | suppressed |
| Dulera | Mometasone/Formoterol | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 25 | suppressed |
| Gabapentin | Gabapentin | 24 | suppressed |
| Ayvakit | Avapritinib | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Kalbitor | Ecallantide | 15 | suppressed |
| Nucala | Mepolizumab | 15 | suppressed |
| Xolair | Omalizumab | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Dupixent Pen | Dupilumab | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Haegarda | C1 Esterase Inhibitor | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Atovaquone | Atovaquone | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Ruconest | C1 Esterase Inhibitor, Recomb | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $58,519.24 · 41 records | Ionis Pharmaceuticals, Inc. | AYVAKIT, Andembry, DAWNZERA, DONIDALORSEN, DUPIXENT, NEMLUVIO, OCTAGAM IMMUNE GLOBULIN (HUMAN), ORLADEYO, PANZYGA, TAKHZYRO, VTAMA, WAYRILZ, Xembify, Xolair | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ayvakit play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Blueprint Medicines Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error